Results 81 to 90 of about 528,594 (306)

COVID‐19 Vaccination Is Not Associated With the Development of Idiopathic Inflammatory Myositis in US Veterans

Arthritis Care &Research, EarlyView.
Objective Several case reports have proposed a potential association between COVID‐19 vaccination and the subsequent development of idiopathic inflammatory myositis (IIM). This study examined prior COVID‐19 vaccination in US veterans who developed new‐onset IIM compared to those without new‐onset IIM.
Caleb Hernández, Naomi Schlesinger, Jorge Rojas, Jessica A. Walsh, Tawnie J. Braaten, Gary A. Kunkel, Makoto Jones, Brian C Sauer, Julio Facelli, Grant W. Cannon, Dorota Lebiedz‐Odrobina   +10 more
wiley   +1 more source

Retrospective Analysis of Familial Clustering for Malignant Melanoma

, 2003
Background: Malignant Melanoma (MM) is familial in 5-7% of cases. Germline mutations of the CDKN2 and CDK4 genes are involved in the pathogenesis of hereditary MM, but the high frequency of familial clustering suggests other genes involved.
DELFINO, MARIO, PENSABENE, MATILDE, SPAGNOLETTI, ILARIA, SCALVENZI, MASSIMILIANO, MOLEA, GUIDO, CAPUANO, IDA, PEPE, STEFANO, CONTEGIACOMO, ALMA, FABBROCINI, GABRIELLA   +8 more
core  

Clinical guidelines for the recognition of melanoma of the foot and nail unit

, 2010
Malignant melanoma is a life threatening skin tumour which may arise on the foot. The prognosis for the condition is good when lesions are diagnosed and treated early.
David AR de Berker, Bristow, I.R., de Berker, D.A.R., Turner Richard J, Bristow Ivan R, Katharine M Acland, Richard J Turner, Jonathan Bowling, Ivan R Bristow, Acland Katharine M, de Berker David AR, Bowling, J., Turner, R.J., Acland, K. M., Bowling Jonathan   +14 more
core   +1 more source

03 | Pancreatic cancer burden in Italian CDKN2a-positive families followed for up to 25 years

Dermatology Reports
Background: Pancreatic cancer (PC) risk in CDKN2A pathogenic variant (PV) carriers is among the highest (more than twice that of BRCA1/2), with a standardized incidence ratio (SIR) of 20 and cumulative incidence of 20% by age 70 in the Dutch cohort ...
Italian Melanoma Intergroup
doaj   +1 more source

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition

Nature Communications, 2020
Transcriptomic signatures designed to predict melanoma patient responses to PD-1 blockade have been reported but rarely validated. We now show that intra-patient heterogeneity of tumor responses to PD-1 inhibition limit the predictive performance of ...
Jenny H. Lee, Elena Shklovskaya, Su Yin Lim, Matteo S. Carlino, Alexander M. Menzies, Ashleigh Stewart, Bernadette Pedersen, Malama Irvine, Sara Alavi, Jean Y. H. Yang, Dario Strbenac, Robyn P. M. Saw, John F. Thompson, James S. Wilmott, Richard A. Scolyer, Georgina V. Long, Richard F. Kefford, Helen Rizos   +17 more
doaj   +1 more source

Marked Long‐Term Improvement in Lung Function in Melanoma Differentiation–Associated Protein 5 Antibody–Positive Dermatomyositis Patients: Experience of a Single‐Center Longitudinal Cohort in North America

Arthritis Care &Research, EarlyView.
Objective The objective of this study was to describe the longitudinal disease course and pulmonary outcomes of North American patients with melanoma differentiation–associated protein 5 (MDA5) antibody–associated dermatomyositis (DM). Methods Thirty patients with MDA5 antibody–associated DM were identified in a single‐center longitudinal cohort of 352
Jenice X. Cheah, Sangmee S. Bae, Tiffany De Leon, Yuna Lee, Rong Guo, David Elashoff, Jennifer Wang, Ani Shahbazian, Christina Charles‐Schoeman   +8 more
wiley   +1 more source

Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy [PDF]

, 2014
Phosphatase and tensin homolog (PTEN) loss is associated with genomic instability. APE1 is a key player in DNA base excision repair (BER) and an emerging drug target in cancer.
Seedhouse, C, Seedhouse, Claire, Simeonov, Anton, Grabowska, Anna, Jewell, Rosalyn, Nsengimana, J, Ball, G, Abbotts, Rachel, Ball, Graham, Elliott, Faye, Walker, Christy, Wilson III, David M, Wilson III, DM, Patel, Poulam M, Elliott, F, Jadhav, Ajit, Grabowska, A, Laye, J, Simeonov, A, Maloney, DJ, Wilson, DM, Maloney, David J, Madhusudan, Srinivasan, Abbotts, R, Nsengimana, J�r�mie, Jadhav, A, Jewell, R, Madhusudan, S, Walker, C, Patel, PM, Newton-Bishop, J, Laye, Jon, Newton-Bishop, Julia   +32 more
core   +1 more source

Immune Checkpoint Inhibitor–Related Myositis and Associated Triad Overlap Syndrome

Arthritis Care &Research, EarlyView.
Objective Immune checkpoint inhibitor (ICI) myositis is a rare but a highly morbid condition, particularly with the ICI myositis triad syndrome of myositis, myocarditis, and myasthenia gravis. We report the clinical characteristics of ICI myositis and all‐cause mortality in these patients.
Selene Rubino, Grant W. Cannon, Brian C. Sauer, Jorge Rojas, Gregory J. Stoddard, Gary A. Kunkel, Jessica A. Walsh, Bryant R. England, Joshua F. Baker, Tawnie J. Braaten   +9 more
wiley   +1 more source

A Molecular Shielding Strategy to Develop Low Protein Binding, Renal Clearable Pan‐Cancer Near‐Infrared Probes

Advanced Functional Materials, EarlyView.
A molecular shielding strategy to convert “protein‐sticky” and “non‐tumor specific” clinical ICG dye, into a “low protein binding” and “tumor‐targeting” dye with prolonged blood circulation and renal clearance is described. These shielded ICGs demonstrate strong tumor accumulation and optimal tissue clearance, resulting in high tumor‐to‐background ...
Li Xiang, Kailin Mooney, Mingchong Dai, Morgan R. Stewart, Samantha Holland, Michael I. Henderson, Samuel Drennan, Ramon F. Barajas Jr., Jared M. Fischer, Adem Yildirim   +9 more
wiley   +1 more source

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M) : preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study [PDF]

, 2014
Background: Bevacizumab, a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. We aimed to assess the role of bevacizumab as adjuvant treatment for patients with resected melanoma at high risk of ...
N. Davidson (7671467), J. P. Nobes (7671491), P. Lorigan (7671500), Harries, M., C. G. Kelly (7671473), A. Marshall (7671452), M. R. Middleton (7671458), Dunn, Janet A, Houston, Stephen J, Board, Ruth E., Steve Nicholson (7671470), Lorigan, P., Waterston, A.M., Nobes, Jenny P., Gore, M.E., Kelly, Charles G, Danson, S., Nathan, Paul D, Nathan, Paul D., Kumar, S., Middleton, Mark R., Davidson, Neville, Marples, M., Nobes, Jenny P, Waterston, Ashita M, Young, G., Dunn, J., Nathan, P.D., Lorigan, Paul; id_orcid, Houston, S., Danson, Sarah J, M. Gore (7671464), Davidson, D., Board, R.E., M. Marples (7671476), Dunn, Janet A., Nobes, J.P., Marshall, E., Corrie, P., S. J. Danson (7671479), Marshall, A., Middleton, Mark R, Board, Ruth E, Middleton, M.R., Marshall, Ernest, Gore, Martin, Marples, Maria, Corrie, Pippa G, P. D. Nathan (7671461), G Young (7671497), E. Marshall (7241588), Houston, Stephen J., Young, Gemma, Nicholson, Steve, A. M. Waterston (7671488), Kelly, Charles G., P. G. Corrie (7671449), S. J. Houston (7671482), Kelly, C.G., Corrie, Pippa G., M. Harries (7671494), Marshall, Andrea, Kumar, Satish, S. Kumar (746162), Nicholson, S., Waterston, Ashita M., R. E. Board (7671485), Harries, Mark, Danson, Sarah J., Marshall, A. (Andrea)‏, Lorigan, Paul, J. A. Dunn (7671455)   +71 more
core   +1 more source